Nancy A. Grygiel - Net Worth and Insider Trading
Nancy A. Grygiel Net Worth
The estimated net worth of Nancy A. Grygiel is at least $3 Million dollars as of 2023-10-05. Nancy A. Grygiel is the SVP & CCO of Amgen Inc and owns about 13,104 shares of Amgen Inc (AMGN) stock worth over $3 Million. Details can be seen in Nancy A. Grygiel's Latest Holdings Summary section.
Transaction Summary of Nancy A. Grygiel
Nancy A. Grygiel Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Nancy A. Grygiel owns 1 companies in total, including Amgen Inc (AMGN) .
Nancy A. Grygiel Latest Holdings Summary
Nancy A. Grygiel currently owns a total of 1 stock. Nancy A. Grygiel owns 13,104 shares of Amgen Inc (AMGN) as of November 8, 2022, with a value of $3 Million.
Nancy A. Grygiel Form 4 Trading Tracker
According to the SEC Form 4 filings, Nancy A. Grygiel has made a total of 2 transactions in Amgen Inc (AMGN) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Amgen Inc is the sale of 545 shares on November 8, 2022, which brought Nancy A. Grygiel around $159,979.
Insider Trading History of Nancy A. Grygiel
Nancy A. Grygiel Trading Performance
Nancy A. Grygiel Ownership Network
Ownership Network List of Nancy A. Grygiel
Ownership Network Relation of Nancy A. Grygiel
Nancy A. Grygiel Owned Company Details
What does Amgen Inc do?
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amjevita (biosimilar Humira).
Who are the key executives at Amgen Inc?
Nancy A. Grygiel is the SVP & CCO of Amgen Inc. Other key executives at Amgen Inc include VP & Finance & CAO Matthew C. Busch , SVP & Human Resources Derek Miller , and SVP & Business Development Rachna Khosla .
Amgen Inc (AMGN) Insider Trades Summary
Over the past 18 months, Nancy A. Grygiel made 1 insider transaction in Amgen Inc (AMGN) with a net sale of 545. Other recent insider transactions involving Amgen Inc (AMGN) include a net sale of 800 shares made by R Sanders Williams , a net sale of 13,500 shares made by Jonathan P Graham , and a net sale of 9,558 shares made by Murdo Gordon .
In summary, during the past 3 months, insiders sold 9,558 shares of Amgen Inc (AMGN) in total and bought 0 shares, with a net sale of 9,558 shares. During the past 18 months, 31,390 shares of Amgen Inc (AMGN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 31,390 shares.
Amgen Inc (AMGN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Amgen Inc Insider Transactions
Nancy A. Grygiel Mailing Address
Above is the net worth, insider trading, and ownership report for Nancy A. Grygiel. You might contact Nancy A. Grygiel via mailing address: One Amgen Center Drive, Thousand Oaks Ca 91320.